{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', 'For subjects with C1-INH function > 50% but < assay LLN, a SERPING-1 gene mutation', 'known or likely to be associated with HAE Type I or II, as assessed during the screening', 'period OR a repeat C1-INH functional level < 50% will be considered acceptable for', 'enrollment.', '5. Access to and ability to use one or more acute medications approved by the relevant', 'competent authority for the treatment of acute attacks of HAE (icatibant, plasma-derived', 'C1-INH, ecallantide, or recombinant C1-INH). Cinryze used for acute treatment of HAE', 'attacks is an acceptable medication for this purpose.', '6.', 'Subjects must be medically appropriate for on-demand treatment as the sole medicinal', 'management for their HAE during the study.', '7.', 'The subject must have at least 2 HAE attacks which meet all the requirements below during', 'the run-in period of a maximum of 56 days from the screening visit.', 'The attacks are unique, which is defined as an attack that does not begin within 48 hours', 'of the end of a previous attack.', 'The attacks must have either been treated, required medical attention or be documented', 'to cause functional impairment based on subject entry in the diary. Functional', 'impairment is defined as the subject not being able to perform their daily activities', 'without restriction (ie, subject records that they are at least slightly restricted in their', 'daily activities during their HAE attack).', 'The attacks must include symptoms of swelling. Symptoms of swelling, in addition to', 'visible swelling, may also include symptoms in the oropharyngeal or abdominal regions', 'which are indicative of internal swelling.', 'The attacks are otherwise confirmed by the Investigator to be HAE attacks.', 'Subjects who have recorded 2 such attacks may be randomized to receive study drug', 'beginning on or after Day 28 of the run-in period; subjects who have recorded at least 3 such', 'attacks may be randomized beginning on or after Day 14 of the run-in period. Under no', 'circumstances should the run-in attack requirement for eligibility be disclosed to study', 'subjects.', '8. Female and male subjects must agree to the contraception requirements and must meet the', 'inclusion criteria regarding contraception, and contraception of female partners (as', 'applicable), as outlined in Section 8.2.1.', 'Note: Contraception is no longer required for male subjects and their female partners under', 'Protocol Version 3.0.', '9. In the opinion of the Investigator, the subject is expected to adequately comply with all', 'required study procedures for the duration of the study. The subject must demonstrate', 'adequate compliance with all study procedures required from the screening visit through', 'randomization, including diary recording of HAE attacks beginning at the Screening visit.', 'Main criteria for exclusion:', '1. Any clinically significant medical or psychiatric condition or medical history that, in the', \"opinion of the Investigator or Sponsor, would interfere with the subject's ability to participate\", 'in the study or increases the risk to the subject by participating in the study.', '2. Dementia, altered mental status, or any psychiatric condition, or stay in an institution further to', 'an official or court order that would prohibit the understanding or rendering of informed', 'consent or participation in the study.', '11']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', '3. Anticipated use of short-term prophylaxis of angioedema attacks for a pre-planned procedure', 'during the screening or study periods (Parts 1 and 2 only).', '4. Concurrent diagnosis of any other type of recurrent angioedema.', '5. Clinically significant abnormal ECG at the screening visit. This includes, but is not limited to, a', \"corrected QT interval using Fridericia's method (QTcF) > 470 msec for women, a QTcF\", '> 450 msec for men, PR interval > 220 msec (both sexes), or ventricular and/or atrial premature', 'contractions that are more frequent than occasional, and/or as couplets or higher in grouping.', '6. Any clinically significant history of angina, myocardial infarction, syncope, clinically', 'significant cardiac arrhythmias, left ventricular hypertrophy, cardiomyopathy, or any other', 'clinically significant cardiovascular abnormality such as poorly controlled hypertension.', '7. Known family history of sudden cardiac death. Family history of sudden death from HAE is not', 'exclusionary.', '8. History of or current implanted defibrillator or pacemaker.', '9. Any abnormal laboratory or urinalysis parameter at screening that, in the opinion of the', 'Investigator, is clinically significant and relevant for this study. A calculated creatinine', 'clearance of VI 30 mL/min or aspartate aminotransferase or alanine aminotransferase value > 3 X', 'the upper limit of the normal reference range value obtained during screening is exclusionary.', '10. Prior enrollment in a BCX7353 study.', '11. Suspected C1-INH resistance in the opinion of the Investigator or Sponsor.', '12. History of alcohol or drug abuse within the previous year prior to the screening visit, or current', 'evidence of substance dependence or abuse (self-reported alcohol intake > 3 drinks/day).', '13. Positive serology for human immunodeficiency virus or current infection with hepatitis B virus', 'or hepatitis C virus.', '14. Pregnant, planning to become pregnant during the study, or nursing.', '15. Positive drugs of abuse screen (unless drug is used as medical treatment with a prescription).', '16. History of severe hypersensitivity to multiple medicinal products or severe', 'hypersensitivity/anaphylaxis with unclear etiology.', '17. Use of androgens or tranexamic acid for prophylaxis of HAE attacks within the 28 days prior to', 'the Screening visit or initiation during the study.', '18. Use of C1-INH for prophylaxis of HAE attacks within the 14 days prior to the Screening visit', 'or initiation during the study. Use of a C1-INH therapy for treatment of attacks is not excluded', 'at any time, nor is C1-INH for preprocedure prophylaxis for an unplanned/unforeseen', 'procedure.', '19. Use of concomitant medications that are metabolized by CYP2D6, CYP2C9, CYP2C19, and', 'CYP3A4 and have a narrow therapeutic range, within 7 days of the baseline visit or planned', 'initiation during the study.', '12']\n\n###\n\n", "completion": "END"}